MicroStrategy eyes $2.6 billion raise for Bitcoin acquisition as it breaks into top 100 US firms

Share This Post

MicroStrategy has increased its convertible debt offering to $2.6 billion, up from its original $1.75 billion target, according to a Nov. 20 statement.

The firm stated that the proceeds from this offering will fund additional Bitcoin acquisitions and other corporate needs.

Offering details

The convertible notes will be sold privately to institutional buyers under Rule 144A of the Securities Act of 1933 and to select non-US investors following Regulation S. MicroStrategy has also given buyers a three-day option to purchase an extra $400 million in notes.

These notes are unsecured senior obligations that mature on Dec. 1, 2029. They do not bear regular interest, and their principal will not accrete.

According to the firm, the initial conversion rate for the notes is 1.4872 shares of MicroStrategy Class A stock per $1,000 of principal, equating to a conversion price of $672.40 per share. This rate reflects a 55% premium over the average price of $433.80 recorded on Nov. 19. Meanwhile, conversion terms may adjust based on certain events.

MicroStrategy said it expects net proceeds from the offering to be $2.58 billion after accounting for expenses. However, if buyers fully exercise the additional purchase option, proceeds could reach $2.97 billion.

Top 100 public companies

The move coincides with MicroStrategy’s rise into the top 100 US publicly traded companies, where it now ranks 97th, according to CompaniesMarketCap data.

This rise was influenced by the firm’s impressive stock performance, which increased by around 100% in the past month to a two-decade high of over $430. The performance has also favorably positioned the firm against the high-performing stocks of AI giants like Nvidia.

As of press time, early market indications suggest that the trend has continued, with the firm’s pre-market trading rising by around 8%, according to Google Finance data.

MicroStrategy remains the largest Bitcoin-holding public company, with over 330,000 BTC worth over $30 billion. This year alone, it has added nearly 150,000 BTC to its holdings, solidifying its position as a leader in corporate Bitcoin adoption.

The post MicroStrategy eyes $2.6 billion raise for Bitcoin acquisition as it breaks into top 100 US firms appeared first on CryptoSlate.

Read Entire Article
spot_img
- Advertisement -spot_img

Related Posts

$4,000 Solana Price Possible As SOL Breaks Out Of Massive Cup And Handle Pattern

The Solana price could be gearing up to reach a new ATH of $4,000, according to an analyst who highlighted its recent breakout from a massive Cup and Handle pattern This bullish signal comes on the

Former FTX CTO Gary Wang Spared Prison Time For Cooperating With Prosecutors

The post Former FTX CTO Gary Wang Spared Prison Time For Cooperating With Prosecutors appeared first on Coinpedia Fintech News Former FTX chief technology officer and close friend of Sam

BIS report on DeFi activity reveals institutional traders heavily outmaneuver retail on Uniswap

The Bank for International Settlements (BIS) has revealed that institutional players dominate liquidity provision on decentralized exchanges (DEXs) like Uniswap, according to a Nov 19 report, In a

Gen Z Trader’s $30K Heist Backfires as Crypto Community Rallies Token to $56M Market Cap

A young trader pulled off a pump-and-dump scheme on the coin called QUANT token, but the crypto community countered by rallying the token’s price Trader Live Streams Token Dump A pump-and-dump

Dogecoin Fibonacci Spiral Puts Price As High As $4.2 As It Enters 3rd Iteration

Crypto analyst Tmilnebml has highlighted a bullish pattern that is forming on the Dogecoin price chart Based on this, the analyst predicted that the DOGE price could rally to as high as $42 as the

Biotechs Going Big On BTC; Hoth Therapeutics To Buy $1 Million In Bitcoin

The post Biotechs Going Big On BTC; Hoth Therapeutics To Buy $1 Million In Bitcoin appeared first on Coinpedia Fintech News In a remarkable development, biopharmaceutical companies have revealed